Pharmaceutical Technology

FEBRUARY 9, 2023

Ibutamoren mesylate is under clinical development by Lumos Pharma and currently in Phase II for Growth Hormone Deficiency. According to GlobalData, Phase II drugs for Growth Hormone Deficiency have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. It is administered orally.

Hormones 100

Hormones Drugs Clinical Trials Clinical Trials 100

XTalks

APRIL 22, 2025

As the prevalence of metabolic diseases such as diabetes, obesity and prediabetes continues to rise globally, there is an urgent need for innovative therapies that move beyond traditional hormone replacement strategies. The Science Behind the Innovation Central to Aphaia Pharmas approach is the restoration of endogenous hormone release.

Hormones 52

Hormones Clinical Research Clinical Trials Clinical Trials 52

XTalks

OCTOBER 23, 2024

Unlike drugs that alter metabolism or appetite by interacting with hormones, the pill functions entirely mechanically. Traditional methods like diet and exercise often fail to provide long-term success, and newer pharmacological options like hormone-based GLP-1 agonists, while effective, can be expensive and carry side effects.

Production 104

Production Hormones Drugs Trials 104

BioSpace

OCTOBER 7, 2020

Pfizer and Opko Health reported their Phase III clinical trial of somatrogan met the primary endpoint compared to Genotropin (somatropin) for treating children 3 to 18 years of age with growth hormone deficiency.

Hormones 75

Hormones Trials Clinical Trials Clinical Trials 75

AuroBlog - Aurous Healthcare Clinical Trials blog

APRIL 23, 2024

Semaglutide (sold as Wegovy and Ozempic) and tirzepatide (sold as Zepbound and Mounjaro) are the most well known in the class of drugs that mimic hormones to reduce feelings of hunger. Drugs like Ozempic are very effective at helping most people who take them lose weight. But does weight come back when you stop using […]

Doctors 189

Doctors Doctor Hormones Drugs 189

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 14, 2022

If you’re someone who has to deal with a period regularly, you’re probably all too familiar with just how much your energy levels can change throughout your cycle thanks to hormonal fluctuations.

Hormones 189

Hormones Clinical Trials Clinical Trials Clinical Research 189

Medical Xpress

JANUARY 10, 2023

For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in the Journal of Urology.

Hormones 75

Hormones Clinical Trials Clinical Trials Trials 75

Pharmaceutical Technology

AUGUST 8, 2022

The US Food and Drug Administration (FDA) has granted approval for a supplemental New Drug Application (sNDA) of Orion and its partner Bayer ’s Nubeqa (darolutamide) plus docetaxel to treat metastatic hormone-sensitive prostate cancer (mHSPC) patients.

Hormones 246

Hormones Clinical Trials Clinical Trials Licensing 246

AuroBlog - Aurous Healthcare Clinical Trials blog

JULY 10, 2023

Available through a collaboration with the consumer-initiated testing business of Quest Diagnostics and Proov, maker of at-home fertility and hormone tests, the Proov Confirm PdG test is the first and only FDA-cleared […]

Hormones 179

Hormones Clinical Trials Clinical Trials Trials 179

Medical Xpress

DECEMBER 8, 2022

In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant (Faslodex) doubled the median progression-free survival compared with placebo plus fulvestrant in the phase III CAPItello-291 clinical trial, according to results presented (..)

Hormones 72

Hormones HR Clinical Trials Clinical Trials 72

Pharmaceutical Technology

JUNE 1, 2023

A prior orchiectomy or receipt of gonadotropin-releasing hormone (GnRH) analogs was also necessary. According to figures from GlobalData’s clinical trials database, research into mCRPC treatments has been on the rise over the past 10 years. Trials peaked at 115 in 2018 before declining to 91 last year.

FDA Approval 244

FDA Approval Hormones Trials Clinical Trials 244

Pharmaceutical Technology

FEBRUARY 24, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

BioTech 365

MARCH 17, 2021

Global Growth Hormone Deficiency Clinical Trials Review, H1 2021 Report – ResearchAndMarkets.com Global Growth Hormone Deficiency Clinical Trials Review, H1 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth Hormone Deficiency – Global Clinical Trials Review, H1, 2021” clinical trials has (..)

Hormones 40

Hormones Clinical Trials Clinical Trials Trials 40

Pharmaceutical Technology

JANUARY 22, 2023

The mutation leads to disordered thyroid hormone transport, which causes patients to experience intellectual and motor disabilities. Egetis is banking on tiratricol, an oral small molecule that restores dysfunctional thyroid hormone signalling, to be the first drug approved for this condition. In clinical trials, the drug showed a 3.8-point

Drugs 317

Drugs Gene Hormones Clinical Trials 317

XTalks

JANUARY 16, 2025

Sling Therapeutics has positive topline results from its Phase IIb/III LIDS clinical trial evaluating its oral small-molecule therapy linsitinib for the treatment of thyroid eye disease (TED). It is a complication of Graves disease, an immune system condition that causes the thyroid gland to make excess amounts of thyroid hormone.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

Medical Xpress

APRIL 28, 2023

The patient-reported outcomes (PROs) of the phase 3 NRG Oncology clinical trial RTOG 0815 comparing dose-escalated radiotherapy (RT) alone to dose-escalated RT combined with short-term (6 months) androgen deprivation therapy (STAD) indicate that the addition of STAD did not significantly impact urinary or bowel quality of life but did significantly (..)

Clinical Trials 70

Clinical Trials Clinical Trials Trials Hormones 70

XTalks

FEBRUARY 5, 2025

a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 in its Phase Ib trial. Metsera, Inc.,

Hormones 59

Hormones Bioavailability Clinical Trials Clinical Trials 59

Medical Xpress

FEBRUARY 10, 2023

A prohibition against puberty blocking hormones and gender-affirming surgeries for minors in Florida was tightened further after a board overseeing doctors eliminated an exception for clinical trials Friday at the request of Florida Gov. Ron DeSantis' administration.

Doctors 94

Doctors Doctor Hormones Clinical Trials 94

XTalks

SEPTEMBER 2, 2020

VK2809 is a novel, oral small molecule thyroid hormone receptor beta agonist that has selectivity for liver tissue. It is now seen as an epidemic within chronic liver disease, particularly as its prevalence has been increasing and paralleling that of obesity, making it a major health concern worldwide.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Insulin 98

STAT News

MARCH 21, 2023

A new obesity treatment being developed by Altimmune met goals for weight loss in a mid-stage clinical trial, but the data showed it doesn’t have a leg up on other popular drugs on the market.

Hormones 98

Hormones Drugs Clinical Trials Clinical Trials 98

Medical Xpress

JANUARY 10, 2025

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.

Clinical Trials 44

Clinical Trials Clinical Trials Trials Hormones 44

Pharmaceutical Technology

FEBRUARY 9, 2023

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. MK-0677 is active growth hormone secretagogue that acts on the growth hormone secretagogue receptor in the anterior pituitary to stimulate the release of growth hormone.

Hormones 100

Hormones Clinical Trials Clinical Trials Drugs 100

XTalks

MARCH 18, 2025

Incytes recent announcement on the topline results from two Phase III clinical trials of povorcitinib in patients with hidradenitis suppurativa has stirred both hope and caution in the market. Janus kinase one (JAK1) plays a central role in the signaling pathways of several inflammatory cytokines.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

FEBRUARY 21, 2025

In the gut, these receptors prompt the release of hormones such as cholecystokinin and GLP-1, which together signal satiety. In a Phase II trial involving patients with hyperphagia, ARD-101 was well tolerated and achieved an approximate eight-point reduction in hunger scores. The competitive landscape is equally dynamic.

Genetics 59

Genetics Hormones Gene Expression Gene 59

XTalks

MARCH 19, 2025

Eneboparatide (AZP-3601), an investigational parathyroid hormone 1 receptor (PTH1R) agonist, met its primary endpoint in the CALYPSO Phase III trial, offering new data for adults with chronic hypoparathyroidism. AstraZeneca received eneboparatide during its $1.05

Trials 59

Trials Hormones Engineer Licensing 59

XTalks

JANUARY 30, 2025

Novartis has spent three decades advancing breast cancer treatments, focusing on hormone receptor-positive (HR+), HER2-negative breast cancer, the most common subtype. Last year, the FDA approved Kisqali (ribociclib) to reduce the risk of recurrence in HR+/HER2- early breast cancer. Novartis dedicated approximately $0.47

HR 64

HR Hormones FDA Approval Clinical Trials 64

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Mainly you see an improvement in complications such as diabetes, because these hormones are acting on the appetite and also in glucose levels. million in Q3.

Drugs 264

Drugs Manufacturing Hormones Clinical Trials 264

Advarra

JUNE 30, 2023

The Centers for Medicare & Medicaid Services (CMS) released a letter outlining routine costs in clinical trials for patients eligible for Medicaid in April 2022. However, a year has passed with no further updates on this letter or Medicaid beneficiaries enrolling in clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Hormones 52

XTalks

APRIL 15, 2025

Since the FDA approved recombinant human growth hormone (rhGH) for PWS in 2000, multiple companies have tried and failed to develop a targeted treatment for hyperphagia. Vykay XR Clinical Trial Results Data from a randomized, placebo-controlled Phase III trial (Study 2-RWP or Study C602-RWP) support Vykat XRs approval.

FDA Approval 59

FDA Approval Clinical Trials Clinical Trials Trials 59

Pharmaceutical Technology

NOVEMBER 30, 2022

We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Mainly you see an improvement in complications such as diabetes, because these hormones are acting on the appetite and also in glucose levels. million in Q3.

Drugs 246

Drugs Manufacturing Hormones Clinical Trials 246

XTalks

MAY 17, 2023

While the exact physiology of vasomotor symptoms is not fully understood, it is believed that the significant fluctuations in reproductive hormones play a role in triggering these symptoms. Hormone replacement therapy is thought to be one of the most effective treatments for vasomotor symptoms. How Does Veozah Work?

Hormones 95

Hormones FDA Approval Drugs Clinical Trials 95

Worldwide Clinical Trials

JULY 8, 2024

Hormonal Status : A body’s hormones, such as levels of reproductive hormones and thyroid function, can impact tissue responses to radiation therapy. Our expertise spans a wide range of therapeutic areas, from oncology to neurology, leveraging advanced imaging techniques and innovative trial designs.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130

XTalks

DECEMBER 13, 2024

Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas. By mimicking this hormone, petrelintide may offer an alternative or complement to incretin-based therapies, known for their role in weight management.

Drugs 102

Drugs Hormones Trials Clinical Trials 102

Pharmaceutical Technology

DECEMBER 21, 2022

This approval is based on findings from the multicentre, double-blind, randomised, placebo-controlled, 12-month Phase III ATOM clinical trial. The trial analysed the safety and efficacy of 80μg abaloparatide in men with osteoporosis. Abaloparatide is a parathyroid hormone-related peptide [PTHrP(1-34)] analog.

Hormones 130

Hormones Clinical Trials Clinical Trials Trials 130

XTalks

NOVEMBER 29, 2023

David Cameron, Chair of the Breast International Group (BIG) , we delve into the landscape of breast cancer research today, clinical trials and the incorporation of the patient voice in breast cancer research. Breakthroughs in Treatment BIG has been at the forefront of numerous clinical trials.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

pharmaphorum

OCTOBER 17, 2022

Bayer has added another clinical trial to its extensive phase 3 programme for oral neurokinin antagonist elinzanetant, hoping to show that it can treat vasomotor symptoms (VMS) in breast cancer patients. There are around 2.3

Trials 111

Trials Hormones Clinical Trials Clinical Trials 111

pharmaphorum

MAY 27, 2021

It is thought that around five million women in the US have uterine fibroids that cause symptoms, with two-thirds of them inadequately treated with current drugs – generally off-label oral contraceptives or injectable gonadotropin releasing hormone (GnRH) agonists like leuprolide acetate or goserelin acetate.

Hormones 98

Hormones Sales Marketing Drugs 98